Co-Diagnostics Reports Q1 Loss of $4.06/Share, Exceeding Prior Expectations
CODX sits 21% above its 52-week low of $1.35 on light trading volume (0.2× avg).
Summary
Co-Diagnostics, Inc. has reported a first-quarter loss of $4.06 per share. This actual loss is significantly worse than the $3.75 per share loss that was anticipated by Reuters just two days prior. The larger-than-expected loss further highlights the company's ongoing financial struggles, especially following its recent S-3 shelf registration for $150 million, which was filed amidst a 'going concern' warning. This negative earnings surprise will likely put additional pressure on the stock and raises further questions about the company's path to profitability and its ability to address its financial challenges.
At the time of this announcement, CODX was trading at $1.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.9M. The 52-week trading range was $1.35 to $46.50. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.